Cantharidin Topical Solution (Ycanth) for Molluscum Contagiosum
The Medical Letter on Drugs and Therapeutics · 2024
DOI: 10.58347/tml.2024.1696b ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Cantharidin, Molluscum Contagiosum.
Abstract (Originalsprache)
The FDA has approved cantharidin 0.7% solution (Ycanth – Verrica) for topical treatment of molluscum contagiosum in patients ≥2 years old. Ycanth was the first drug to be approved in the US for this indication. A 10.3% gel formulation of berdazimer (Zelsuvmi), a nitric oxide-releasing agent, has also been approved by the FDA for treatment of molluscum contagiosum (in patients ≥1 year old); it will be reviewed in a future issue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2024). Cantharidin Topical Solution (Ycanth) for Molluscum Contagiosum. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1696b
Vancouver
Cantharidin Topical Solution (Ycanth) for Molluscum Contagiosum. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1696b
BibTeX
@article{euvimed2024,
title = {Cantharidin Topical Solution (Ycanth) for Molluscum Contagiosum},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2024},
doi = {10.58347/tml.2024.1696b}
}
EUVIMED